Targeting Regulatory T cells (Tregs)

According to the most current advances in research, Tregs are the central regulating element for general immunological processes.
Today, the scientific community is convinced that in all autoimmune and chronic inflammatory conditions a severe functional deficiency of Tregs occurs. This has already been shown in a number of diseases, including but not restricted to the key indication areas of IMTM’s development portfolio.

PETIR™ drugs significantly activate the regulatory phenotype of human natural Tregs.

Thereby PETIR™ drugs lead to a significant reduction of the inflammatory processes and are ideally suited for use in immunologically dependent chronic diseases. These include but are not restricted to

  • Acne
  • Psoriasis
  • Atopic Dermatitis
  • Crohn’s disease and ulcerative colitis (IBD)
  • Multiple sclerosis
  • Bronchial asthma and other allergies
  • Transplant rejections and
  • Atherosclerosis

The advantage of this novel therapeutic approach in comparison with conventional anti-inflammatory and immunomodulating therapies bases on its action in the centre of the inflammatory process via the activation of regulatory T cells and induction of potent anti-inflammatory cytokines in parallel to a down regulation of activated cells.